CASP9 and B-cell chronic lymphocytic leukemia: To test this hypothesis, we performed flow cytometric analysis of Bax activation as well as of markers of post-mitochondrial apoptosis (cleaved caspase-9 and cleaved PARP) in agonist mix–treated primary CLL cells (as described in Supplemental Figure 1).